Watanabe, K.; Saito, R.; Miyauchi, E.; Nagashima, H.; Nakamura, A.; Sugawara, S.; Tanaka, N.; Terasaki, H.; Fukuhara, T.; Maemondo, M.
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation. Cancers 2023, 15, 4231.
https://doi.org/10.3390/cancers15174231
AMA Style
Watanabe K, Saito R, Miyauchi E, Nagashima H, Nakamura A, Sugawara S, Tanaka N, Terasaki H, Fukuhara T, Maemondo M.
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation. Cancers. 2023; 15(17):4231.
https://doi.org/10.3390/cancers15174231
Chicago/Turabian Style
Watanabe, Kana, Ryota Saito, Eisaku Miyauchi, Hiromi Nagashima, Atsushi Nakamura, Shunichi Sugawara, Nobuyuki Tanaka, Hiroshi Terasaki, Tatsuro Fukuhara, and Makoto Maemondo.
2023. "Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation" Cancers 15, no. 17: 4231.
https://doi.org/10.3390/cancers15174231
APA Style
Watanabe, K., Saito, R., Miyauchi, E., Nagashima, H., Nakamura, A., Sugawara, S., Tanaka, N., Terasaki, H., Fukuhara, T., & Maemondo, M.
(2023). Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation. Cancers, 15(17), 4231.
https://doi.org/10.3390/cancers15174231
